Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $21.86 USD
Change Today -0.35 / -1.58%
Volume 360.6K
OMER On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

201 Elliott Avenue West

Seattle, WA 98119

United States

Phone: 206-676-5000

Fax: 206-676-5005

tent applications owned by Daiichi Sankyo for use in the treatment of movement disorders and other specified indications, addiction and compulsive disorders, and all other diseases except those related to dermatologic conditions. Plasmin Program - OMS616 The company is developing antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma or other hyperfibrinolytic conditions. The company has selected a lead clinical candidate and is preparing to manufacture preclinical supplies to enable the initiation of good laboratory practices toxicology studies intended to support the submission of an investigational new drug application or clinical trial application and subsequent clinical trials. The company has a license agreement with The Regents of the University of California, or The Regents, pursuant to which it received an exclusive license to a series of antifibrinolytic agents claimed in certain patents owned by The Regents in exchange for its agreement to make royalty and development milestone payments. GPR17 Program The company is optimizing compounds against GPR17, a G protein-coupled receptor (GPCR), which is linked to myelin formation. The company's proprietary ex vivo platform for the discovery of novel, high-affinity monoclonal antibodies, which was in-licensed from the University of Washington and then further developed by its scientists, utilizes a chicken B-cell lymphoma cell line and has demonstrated potential for the generation of diverse antibodies that can be readily engineered. Sales and Marketing The company has retained all marketing and distribution rights to its products and programs, which provides it the opportunity to market and sell any of its products independently, make arrangements with third parties to perform these services for it, or both. Manufacturing In March 2014, the company entered into an agreement with DSM Pharmaceuticals, Inc. (DSM), pursuant to which DSM has agreed to manufacture and supply commercial quantities of Omidria, if approved. Pursuant to the Agreement, DSM has agreed to manufacture and supply, and the company has agreed to purchase, a minimum percentage of its commercial requirements for Omidria in the U.S. during a term ending December 31, 2015. The company has also entered into agreements with Hospira Worldwide, Inc. (Hospira), pursuant to which Hospira has manufactured three registration batches of liquid OMS103 at its facility in McPherson, Kansas, and agreed to manufacture and supply commercial requirements of liquid OMS103, if approved for marketing. Intellectual Property As of February 15, 2014, the company owned or held worldwide exclusive licenses to a total of 51 issued or allowed patents and 51 pending patent applications in the U.S. and 245 issued or allowed patents and 230 pending patent applications in foreign markets directed to therapeutic compositions and methods related to its development programs. The company's patent portfolio for its PharmacoSurgery technology is directed to locally delivered compositions and treatment methods using agents selected from broad therapeutic classes. These patents and patent applications are directed to combinations of agents, generic and/or proprietary to the company or others, delivered locally and intraoperatively to the site of any medical or surgical procedure. As of February 15, 2014, the company's patent portfolio included 18 U.S. and 74 foreign issued or allowed patents, and 8 U.S. and 23 foreign pending patent applications, directed to its PharmacoSurgery products and development programs. The company's issued PharmacoSurgery patents have terms that would expire as late as September 24, 2022 for OMS103 and July 30, 2023 for Omidria, and, if pending patent applications are issued, August 3, 2032 for OMS103, October 23, 2033 for Omidria and March 17, 2026 for OMS201. Omidria-Ophthalmology: As of February 15, 2014, the company owned 2 issued U.S. Patents and 3 pending U.S. Patent Applications and 28 issued patents and 11 pending patent applications in foreign markets (Argentina, Australia, Canada, China, Europe, Hong Kong, Japan and Interna


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $21.86 USD -0.35

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies

Industry Analysis


Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,383.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,459.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at